School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; Clinical Pharmacy (School of Integrative Pharmacy, Institute of Integrative Pharmaceutical Research), Guangdong Pharmaceutical University, Guangzhou 510006, China.
Bioorg Med Chem. 2020 Jun 1;28(11):115527. doi: 10.1016/j.bmc.2020.115527. Epub 2020 Apr 22.
Based on DNA topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibition of the ethanol extract of the roots of Isodon ternifolius (D. Don) Kudo (Labiatae), its secondary metabolites has been studied. Two new compounds, an ent-abietane diterpenoid isodopene A (1) and a 2,3-seco-triterpene isodopene B (13), along with 25 known compounds were isolated. Their structures were elucidated by spectroscopic analysis and theoretical calculations. The enzyme-based assays indicated that 1 and 13 showed strong (+++) and moderate (++) TOP1 inhibition, respectively. Two chalcone derivatives 11 and 12 were firstly found as dual TDP1 and TOP1 natural inhibitors, and showed synergistic effect with the clinical TOP1 inhibitors topotecan in MCF-7 cells. Compounds 8, 16, and 22 acted as TOP1 catalytic inhibitors with equipotent TOP1 inhibition to camptothecin (++++). Compounds 7 and 8 exhibited significant cytotoxicity against MCF-7, A549, and HCT116 cells with GI values in the range of 2.2-4.8 μM. This work would provide valuable information that secondary metabolites from I. ternifolius could be developed as anticancer agents.
基于 DNA 拓扑异构酶 IB(TOP1)和酪氨酰-DNA 磷酸二酯酶 1(TDP1)对 Isodon ternifolius(D. Don)Kudo(唇形科)根的乙醇提取物的抑制作用,研究了其次生代谢产物。分离得到了两种新化合物,即 ent-abietane 二萜类化合物异胡薄荷烯 A(1)和 2,3-裂环三萜类化合物异胡薄荷烯 B(13),以及 25 种已知化合物。通过光谱分析和理论计算确定了它们的结构。基于酶的测定表明,1 和 13 分别表现出强烈的(+++)和中度的(++)TOP1 抑制作用。两种查尔酮衍生物 11 和 12 首次被发现为双重 TDP1 和 TOP1 天然抑制剂,并且在 MCF-7 细胞中与临床 TOP1 抑制剂拓扑替康表现出协同作用。化合物 8、16 和 22 作为 TOP1 催化抑制剂,对喜树碱的 TOP1 抑制作用与喜树碱相当(++++)。化合物 7 和 8 对 MCF-7、A549 和 HCT116 细胞表现出显著的细胞毒性,GI 值范围为 2.2-4.8 μM。这项工作将为从 I. ternifolius 中开发抗癌药物提供有价值的信息。